M&A Archives - Page 34 of 36

M&A

Post-Merger T-Mobile Won’t Be Maverick: States’ Expert

By Chris Nolter

Published: December 12th, 2019

An expert witness for the group of states suing to block T-Mobile's purchase of Sprint testified that the post-merger company would likely lose its zeal for aggressive price competition.

M&A

Merck Expands Oncology Pipeline With ArQule

Published: December 9th, 2019

The biopharmaceutical giant is paying a 107% premium for the target, which focuses on therapies for treating cancer and rare diseases.

M&A

Drinks With The Deal: Chris Varelas

By David Marcus

Published: December 6th, 2019

The former Citi tech investment banker and author of 'How Money Became Dangerous' talks with The Deal’s David Marcus about working at Disneyland in the 1980s, being a tech banker after the dot-com crash and investing in influencers.

M&A

Thoma Bravo Takes Instructure Private Following Review

By Steve Gelsi

Published: December 4th, 2019

The $2 billion bid comes after the company announced a strategic review in October and after The Deal named the information tech company a target in January.

M&A

Discipline Crucial in 2020

By Alexandra Garfinkle

Published: December 2nd, 2019

M&A valuations remain frothy and Ebitda adjustments are growing, panelists cautioned at The 2019 Deal Economy Conference.

Activism

Vitamin Shoppe to Emphasize Organic Growth

By Alexandra Garfinkle

Published: December 2nd, 2019

Vitamin Shoppe GC David Kastin said that the company will pursue organic growth, while its soon-to-be parent pursues M&A.

Activism

Activists Find New Routes to M&A Opportunities

By Ronald Orol

Published: December 2nd, 2019

Insurgent managers are targeting larger companies and are taking on different roles, a panel of experts told The Deal Economy's 2019 conference.

Activism

M&A, Politics, SEC Top of Mind for Activists

By Ronald Orol

Published: December 2nd, 2019

Schulte Roth partner Aneliya Crawford discusses activism at large-cap companies, BMY-Celgene and insurgent prospects in a second Trump or Warren administration at The Deal Economy conference.

M&A

Pfizer Leans Toward Tuck-In Deals

By Armie Margaret Lee

Published: November 27th, 2019

This year, Pfizer’s first under the leadership of Albert Bourla, the biopharma company has done deals including the purchase of Array BioPharma and Therachon.

Insights & Analysis

Page 34

Post-Merger T-Mobile Won’t Be Maverick: States’ Expert

Merck Expands Oncology Pipeline With ArQule

Drinks With The Deal: Chris Varelas

Thoma Bravo Takes Instructure Private Following Review

Discipline Crucial in 2020

Vitamin Shoppe to Emphasize Organic Growth

Activists Find New Routes to M&A Opportunities

M&A, Politics, SEC Top of Mind for Activists

Pfizer Leans Toward Tuck-In Deals

Join our community of dealmakers and advisers